XORTX Therapeutics (TSXV:XRTX) Common Stock: C$27.69 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:XRTX XORTX Therapeutics Inc TSXV:XRTX
30 GF Score
Price C$2.84
! 1 Warning Sign
View Full Analysis

What is XORTX Therapeutics Common Stock?

XORTX Therapeutics TSXV:XRTX 30 Common Stock is C$27.69 Mil as of Mar. 2026. GuruFocus rates TSXV:XRTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

XORTX Therapeutics's quarterly common stock increased from Sep. 2025 (C$26.96 Mil) to Dec. 2025 (C$27.84 Mil) but then declined from Dec. 2025 (C$27.84 Mil) to Mar. 2026 (C$27.69 Mil).

XORTX Therapeutics's annual common stock increased from Dec. 2023 (C$22.88 Mil) to Dec. 2024 (C$26.35 Mil) and increased from Dec. 2024 (C$26.35 Mil) to Dec. 2025 (C$27.84 Mil).

XORTX Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for XORTX Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XORTX Therapeutics Common Stock Chart

XORTX Therapeutics Annual Data
Trend Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.59 22.45 22.88 26.35 27.84

XORTX Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.15 25.85 26.96 27.84 27.69
TSXV:XRTX
30GF Score
XORTX Therapeutics Inc TSXV:XRTX
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XORTX Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of C$27.69 Mil mean?
XORTX Therapeutics (TSXV:XRTX) has a Common Stock of C$27.69 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on XORTX Therapeutics and its competitors.
Is XORTX Therapeutics' Common Stock too high?
XORTX Therapeutics' current Common Stock is C$27.69 Mil. Overall, XORTX Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does XORTX Therapeutics' Common Stock compare to VRTX and REGN?
XORTX Therapeutics' Common Stock of C$27.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on XORTX Therapeutics and its competitors. XORTX Therapeutics's current Common Stock is C$27.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XORTX Therapeutics stock overvalued right now?
XORTX Therapeutics (TSXV:XRTX) has a current Common Stock of C$27.69 Mil. The current Common Stock is C$27.69 Mil. XORTX Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For XORTX Therapeutics (TSXV:XRTX), the current Common Stock is C$27.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XORTX Therapeutics Business Description

Other Exchanges XRTX:USAANU:Germany
Address 3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
30GF Score

Get the complete analysis for TSXV:XRTX

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$2.84
Price